 Equities research analysts at Maxim Group began coverage on shares of Moleculin Biotech NASDAQ:MBRX in a report issued on Tuesday, TipRanks reports. The brokerage set a buy rating and a 3.00 price target on the stock. Maxim Groups price objective would indicate a potential upside of 156.41 from the stocks previous close. Several other analysts ... 